RZLT · Biotech · Nasdaq · As of 21 Nov 2026
Rezolute, Inc. stock: filings, catalysts and timeline
Sign in to follow
AIR Score
Cautious · 47 / 100
AIR confidence
Support behind the full AIR read.
What is this? →Hide
How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.
The Discovery Gap
Very high
Gap confidence
How fully AIR could measure this Gap — separate from the AIR Score's confidence.
What is this? →Hide
How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.
Five perspectives
FundamentalsWhat is this?HideNot scored — outside AIR's $300M–$20B fundamentals band
How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.
Source: SEC XBRL financial statements.
ValueWhat is this?HidePre-revenue — no valuation basis
How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.
Source: SEC XBRL financial statements and end-of-day prices.
News flowWhat is this?HideBalanced
What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.
Source: SEC EDGAR 8-K filings and FDA approvals.
MomentumWhat is this?HideWatch
The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.
Source: End-of-day prices.
SafetyWhat is this?HideBalanced
The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.
Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.
Rating words, not raw numbers.
Discovery Gap: Very high (55/100) · Gap confidence 56/100
Discovery gap
Documented progress is running well ahead of market attention.
Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.
What is this?Hide
How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.
Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.
How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.
This month at a glance
Evidence timeline
What changed — last 90 days
As of 17 Nov 2026The company reported FY2026 net loss of $77.6M versus $74.4M prior year, with cash declining to $107.8M from $167.9M.
Results · 8-K filed 24 Sep →
The company filed its annual report for FY2026.
Quarterly/annual report · 10-K filed 24 Sep →
The company reported Q1 FY2027 results with Phase 3 upLIFT tumor HI study enrollment completion, 7 of 8 early participants meeting primary endpoint.
Results · 8-K filed 5 Nov →
The company filed its quarterly report for the period ending 30 September 2026.
Quarterly/annual report · 10-Q filed 5 Nov →
The company completed pricing of approximately $100M underwritten offering of common stock and pre-funded warrants, with net proceeds of approximately $93.5M.
Major contract · 8-K filed 16 Nov →
What the company disclosed, not verified by AIR · sources link to the Evidence timeline below.
- Expected
Fri 12 Feb · expected 10-Q
Last year filed 12 Feb 2026.
Fri 24 Sep · expected 10-K
Last year filed 24 Sep 2026.
- Filed
Mon 16 Nov · 8-K
8-K · Item 1.01 — Material agreement
Rezolute completed pricing of ~$100M underwritten offering of common stock and pre-funded warrants, led by Frazier Life Sciences. Net proceeds (~$93.5M) will fund ersodetug commercialization preparation, working capital, and general corporate purposes.
Recognition: Watch 42 → Balanced 46Gap High · 34 → Very high · 57More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
Fri 13 Nov · 8-K
8-K · Item 8.01 — Other events
Gap Medium · 20 → Very high · 58Progress is running ahead of attention.
Thu 5 Nov · 10-Q
Quarterly report (10-Q), period ending 30 Sep 2026
Gap Low · 6 → Medium · 20Progress is running ahead of attention.
The price trend weakened.
Thu 5 Nov · 8-K
8-K · Item 2.02 — Results of operations
Rezolute reported Q1 FY2027 results with enrollment completion in Phase 3 upLIFT tumor HI study (topline mid-December 2026), 7 of 8 early participants met primary endpoint, and FDA recommended BLA filing for congenital HI despite prior primary endpoint miss.
Gap Low · 6 → Medium · 20Progress is running ahead of attention.
The price trend weakened.
Thu 29 Oct · 8-K
Wed 14 Oct · 8-K
Recognition: Balanced 46 → Watch 43Gap Medium · 18 → Low · 5Market attention has faded.
The gap narrowed as the filings read less positively.
The price trend weakened.
Mon 5 Oct · 8-K
Gap High · 28 → Medium · 17The gap narrowed as the filings read less positively.
The price trend strengthened.
Thu 24 Sep · 8-K
8-K · Item 2.02 — Results of operations
Rezolute reported FY2026 results with net loss of $77.6M (vs. $74.4M prior year), cash decline to $107.8M (from $167.9M), and mixed clinical progress. Tumor HI Phase 3 upLIFT shows positive interim data (7 of 8 responders), but congenital HI Phase 3 sunRIZE failed primary endpoint with FDA review ongoing.
Thu 24 Sep · 10-K
Tue 2 Jun · 8-K
Tue 12 May · 8-K
Tue 12 May · 10-Q
Quarterly report (10-Q), period ending 31 Mar 2026
Mon 4 May · 8-K
Tue 24 Mar · 8-K
Thu 12 Feb · 8-K
Thu 12 Feb · 10-Q
Quarterly report (10-Q), period ending 31 Dec 2025
Wed 7 Jan · 8-K
Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.
Ask AIR
What would change our view
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.